Head to Head Review: Nyxoah (NASDAQ:NYXH) and Enovis (NYSE:ENOV)

Enovis (NYSE:ENOV) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

98.5% of Enovis shares are held by institutional investors. 2.7% of Enovis shares are held by insiders. Comparatively, 17.1% of Nyxoah shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Enovis and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enovis	-52.69%	8.74%	4.19%
Nyxoah	-1,457.97%	-101.99%	-66.74%

Earnings and Valuation

This table compares Enovis and Nyxoah”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25 billion	0.62	-$1.18 billion	($20.71)	-1.18
Nyxoah	$4.89 million	26.05	-$64.10 million	($2.49)	-1.50

Nyxoah has lower revenue, but higher earnings than Enovis. Nyxoah is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Enovis has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Enovis and Nyxoah, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1	0	7	1	2.89
Nyxoah	1	0	3	1	2.80

Enovis presently has a consensus price target of $47.43, indicating a potential upside of 93.67%. Nyxoah has a consensus price target of $11.67, indicating a potential upside of 211.94%. Given Nyxoah’s higher possible upside, analysts clearly believe Nyxoah is more favorable than Enovis.

Summary

Enovis beats Nyxoah on 8 of the 14 factors compared between the two stocks.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.